Better. With that single word Randy Mills, our President and CEO, starts and ends his letter in our 2015 Annual Report and lays out the simple principle that guides the way we work at CIRM. Better. But better what? “Better infrastructure to translate early stage ideas into groundbreaking clinical trials. Better regulatory practices to advance … Continue reading A look back at the last year – but with our eyes firmly on the future
CIRM Board
Dr. Deborah Deas joins CIRM Board
Dr. Deborah Deas is clearly not someone who opts for the quiet life. If she were, she would have stayed home in Adams Run, the tiny town in rural South Carolina where she was born. The website, NeighborhoodScout.com describes Adams Run (current population 1,492) as: “One of the quietest neighborhoods in America. When you are … Continue reading Dr. Deborah Deas joins CIRM Board
CIRM Board targets diabetes and kidney disease with big stem cell research awards
A recent study estimated there may be more than 500 million people worldwide who have diabetes. That’s an astounding figure and makes diabetes one of the largest chronic disease epidemics in human history. One of the most serious consequences of untreated or uncontrolled diabetes is kidney damage. That can lead to fatigue, weakness, confusion, kidney … Continue reading CIRM Board targets diabetes and kidney disease with big stem cell research awards
Accelerating the drive for new stem cell treatments
Acceleration is defined as the “increase in the rate or speed of something.” For us that “something” is new stem cell treatments for patients with unmet medical needs. Today our governing Board just approved a $15 million partnership with Quintiles to help us achieve that acceleration. Quintiles was awarded the funding to create a new … Continue reading Accelerating the drive for new stem cell treatments
What’s the big idea? Or in this case, what’s the 19 big ideas?
Have you ever stood in line in a supermarket checkout line and browsed through the magazines stacked conveniently at eye level? (of course you have, we all have). They are always filled with attention-grabbing headlines like “5 Ways to a Slimmer You by Christmas” or “Ten Tips for Rock Hard Abs” (that one doesn’t work … Continue reading What’s the big idea? Or in this case, what’s the 19 big ideas?
How to handle CRISPR: Formulating a responsible approach to gene-editing
In February 2016, CIRM sponsored a workshop to discuss the impact of CRISPR, a gene-editing tool that is transforming stem cell research. The workshop was designed to enable the Standards Working Group (SWG) to reflect on policies governing the review and oversight of embryo research support by CIRM. After the workshop, we wrote a blog … Continue reading How to handle CRISPR: Formulating a responsible approach to gene-editing
Rare disease underdogs come out on top at CIRM Board meeting
It seems like an oxymoron but one in ten Americans has a rare disease. With more than 7,000 known rare diseases it’s easy to see how each one could affect thousands of individuals and still be considered a rare or orphan condition. Only 5% of rare diseases have FDA approved therapies People with rare … Continue reading Rare disease underdogs come out on top at CIRM Board meeting
New stem cell approach targeting deadly blood cancers
Every four minutes someone in the US is diagnosed with a blood cancer. It might be lymphoma or leukemia, myeloma or myelodysplastic syndromes (MDS). While we have made great strides in treating some of these over the years, we still have a long way to go. Need proof? Well, every nine minutes someone in the US … Continue reading New stem cell approach targeting deadly blood cancers
Timing is everything: could CRISPR gene editing push CIRM to change its rules on funding stem cell research?
Talk about timely. When we decided, several months ago, to hold a Standards Working Group (SWG) meeting to talk about the impact of CRISPR, a tool that is transforming the field of human gene editing, we had no idea that our meeting would fall smack in the midst of a flurry of news stories about … Continue reading Timing is everything: could CRISPR gene editing push CIRM to change its rules on funding stem cell research?
Board gives stem cell institute marching orders, and a road map
The poet T. S. Eliot once wrote: “If you aren't in over your head, how do you know how tall you are?” Well, everyone at CIRM, California’s stem cell institute, is about to find out how tall we are. Yesterday our governing Board approved a new Strategic Plan. To call it ambitious might be considered … Continue reading Board gives stem cell institute marching orders, and a road map
The Stem Cellar 